BCYC earnings analysis
What we found in BCYC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bicycle Therapeutics (BCYC) reported Q4 2025 results with remarkable revenue growth of 1,170% sequentially to $48 million, significantly exceeding analyst expectations. Despite a narrower loss per share of -$0.29 compared to -$0.88 in Q3 2025, ongoing operational challenges and termination of key collaborations pose risks to future performance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Surge
- Revenue for Q4 2025 was $48 million, up from $12 million in Q3 2025, representing a 300% increase year-over-year.
- Narrowed EPS Loss
- EPS improved to -$0.29 in Q4 2025 compared to -$0.85 in Q3 2025, reflecting a positive trend toward reduced losses.
- Robust Cash Position
- As of March 31, 2026, cash and cash equivalents were reported at $559.5 million, sufficient to cover operational costs for over 12 months.
- Maintained Gross Margin
- Gross margin remained at a strong 100%, consistent with previous quarters, indicating effective cost management.
- Collaboration Milestones
- Despite recent contract terminations, the pipeline remains active with ongoing trials for nuzefatide pevedotin.
- R&D Focus Intensified
- Strategic reprioritization towards promising oncology drugs in the pipeline, particularly BDC and BRC molecules.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Collaboration Agreements Terminated
- Termination of collaborations with Genentech and Novartis may significantly impact future revenue streams and pipeline advancements.
- High Operational Losses
- Continued significant operating losses, exceeding $60 million in Q4 2025, raise concerns regarding financial sustainability.
- Clinical Development Risks
- Ongoing trials may not yield favorable results, affecting the future efficacy and approval of key drug candidates.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.29
- Gross margin
- 100.0%
What they said about what is next.
Management has not provided specific forward guidance for revenue or EPS in the filing.
The filing reads better than the one before it.
What came before.
- 10-K · March 17, 2026
- Bicycle Therapeutics (BCYC) is a clinical‑stage pharma company focused on its proprietary Bicycle® molecules and a reprioritized oncology pipeline led by nuzefatide pevedotin (EphA2). The 2025 filing highlights a…
- 10-Q · August 8, 2025
- Bicycle Therapeutics reported Q2 revenue of $2.92M and a net loss of $78.95M (EPS -$1.14), driven by significantly higher R&D spending. Cash remains large at $721.5M but fell $158.1M over the six months; operating cash…
- 10-Q · May 1, 2025
- Bicycle Therapeutics exhibited a notable improvement in revenue with Q1 2025 revenue reaching $9.977 million, up 469% from $1.75 million in Q1 2024. However, the company reported a net loss of $60.754 million, a…
- 10-Q · October 31, 2024
- Bicycle Therapeutics reported Q3 collaboration revenue of $2.676 million and a net loss of $50.8 million (EPS -$0.74) for the three months ended September 30, 2024. Collaboration revenue declined versus the prior-year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BCYC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever